What is HC Wainwright’s Forecast for FHTX FY2026 Earnings?

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Research analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for Foghorn Therapeutics in a report released on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of $0.09 per share for the year, up from their prior estimate of ($0.91). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Foghorn Therapeutics’ Q4 2026 earnings at ($0.34) EPS, Q1 2027 earnings at ($0.36) EPS, Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.37) EPS, Q4 2027 earnings at ($0.39) EPS, FY2027 earnings at ($1.47) EPS, FY2028 earnings at ($1.46) EPS, FY2029 earnings at ($1.44) EPS and FY2030 earnings at ($1.43) EPS.

Foghorn Therapeutics (NASDAQ:FHTX) last posted its earnings results on Monday, November 9th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $1.04. Foghorn Therapeutics had a negative return on equity of 13.46% and a net margin of 8.40%. The company had revenue of $83.54 million for the quarter, compared to analyst estimates of $7.10 million.

Several other equities analysts also recently weighed in on the stock. Stifel Nicolaus set a $5.00 target price on shares of Foghorn Therapeutics in a report on Thursday, October 1st. Evercore downgraded shares of Foghorn Therapeutics from an “outperform” rating to an “in-line” rating and set a $3.00 price target on the stock. in a report on Tuesday, October 13th. Wedbush downgraded shares of Foghorn Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $10.00 to $2.00 in a report on Friday, October 2nd. Citigroup lowered shares of Foghorn Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Thursday, October 1st. Finally, Weiss Ratings raised shares of Foghorn Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Monday. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Foghorn Therapeutics currently has an average rating of “Hold” and a consensus target price of $6.14.

Foghorn Therapeutics Stock Up 10.0%

Foghorn Therapeutics stock opened at $2.09 on Thursday. Foghorn Therapeutics has a 52 week low of $1.79 and a 52 week high of $7.61. The firm’s 50-day simple moving average is $2.90 and its 200 day simple moving average is $4.56. The firm has a market capitalization of $124.11 million, a PE ratio of 29.86 and a beta of 3.22.

Institutional Trading of Foghorn Therapeutics

A number of large investors have recently made changes to their positions in FHTX. BlackRock Inc. purchased a new stake in Foghorn Therapeutics during the 2nd quarter worth about $12,819,000. Renaissance Technologies LLC lifted its holdings in Foghorn Therapeutics by 36.5% in the 1st quarter. Renaissance Technologies LLC now owns 406,425 shares of the company’s stock valued at $1,943,000 after purchasing an additional 108,689 shares in the last quarter. Candriam S.C.A. purchased a new position in Foghorn Therapeutics in the 1st quarter valued at about $1,500,000. Squarepoint Ops LLC boosted its stake in shares of Foghorn Therapeutics by 25.6% during the 2nd quarter. Squarepoint Ops LLC now owns 130,346 shares of the company’s stock worth $636,000 after purchasing an additional 26,603 shares during the last quarter. Finally, SCS Capital Management LLC acquired a new stake in shares of Foghorn Therapeutics during the 2nd quarter worth about $522,000. Institutional investors and hedge funds own 61.55% of the company’s stock.

Recent Foghorn Therapeutics Headlines

These are some of the FHTX headlines that stood out recently:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $5 price target, and raised its FY2026 EPS forecast from a loss of $0.91 to earnings of $0.09. That revision is a positive near-term signal, though it contrasts with the firm’s weaker later-year projections. HC Wainwright estimates and rating
• Negative Sentiment: HC Wainwright cut its FY2027–FY2030 EPS estimates substantially, from prior loss forecasts of roughly $0.65–$0.67 per share to losses of about $1.43–$1.47. It also lowered its Q4 2026 estimate to a $0.34-per-share loss from a $0.23 loss. The revisions point to a more difficult earnings outlook and may weigh on sentiment. HC Wainwright earnings estimates
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of Foghorn investors. The announcement does not establish wrongdoing, but the investigation could add uncertainty and legal risk for shareholders. Pomerantz investor investigation announcement

About Foghorn Therapeutics

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for cancer. Its research centers on chromatin regulatory systems, which help control how genes are expressed and can contribute to disease when disrupted. The company’s Gene Traffic Control platform is designed to identify drug targets within these systems. Foghorn has developed investigational programs targeting chromatin regulators, including components of the BAF complex; its candidates remain in development and are not approved medicines.